In Silico Bioequivalence – to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
Covid19- a global pandemic caused by the SARS-CoV-2 virus. In response to the pandemic, researchers are exploring innovative approaches, such as in silico methods, to enhance the efficacy of COVID-19 vaccines and address the challenges associated with traditional vaccine development.
To determine the potential inclusion of novel vaccine components, including those from BCG and DTP vaccines?
BIOINFORMATICS: Selection Of Components
Test T and B cell reactivity– Test epitope activity to establish antigenicity.
AGENT-BASED MODEL: Dynamic simulations
Agent-based Immune System Simulation- Simulate effect on disease progression in virtual patients.
In silico Quantitative Structure-Toxicity Relationship (QSTR) Model for Predicting Toxicity of Aromatic Aldehydes using Extended Topochemical Atom (ETA) Indices.
In silico SD Bioequivalence trial to replace clinical trial
In silico clinical trial to support label extension.
Connect with our in silico team of experts to discuss AI solutions and advanced modeling and simulation for the Pharma and Life Science industries and hyper accelerate your success
Our Locations
Copyrights 2024 Ikiminds Pvt Ltd. All Rights Reserved